These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 3185701)

  • 1. Generic drug manufacturers lose patent protection battle.
    McGourty C
    Nature; 1988 Oct; 335(6193):756. PubMed ID: 3185701
    [No Abstract]   [Full Text] [Related]  

  • 2. Patent. Battle lines are drawn over generic AIDS drug.
    AIDS Policy Law; 2005 Aug; 20(16):6. PubMed ID: 16161208
    [No Abstract]   [Full Text] [Related]  

  • 3. The Drug Price Competition and Patent Term Restoration Act of 1984: fine-tuning the balance between the interests of pioneer and generic drug manufacturers.
    Soehnge H
    Food Drug Law J; 2003; 58(1):51-80. PubMed ID: 12739584
    [No Abstract]   [Full Text] [Related]  

  • 4. Are the UK courts clamping down on 'evergreening' strategies for the extension of patent protection?
    Albutt J
    Pharm Pat Anal; 2015 Jan; 4(1):1-3. PubMed ID: 25565154
    [No Abstract]   [Full Text] [Related]  

  • 5. Patent protection upheld in Amgen/Genetics Institute battle over EPO.
    Riley J; Pristave R
    Nephrol News Issues; 1991 Apr; 5(4):18-9. PubMed ID: 1961279
    [No Abstract]   [Full Text] [Related]  

  • 6. Brand-name drug manufacturers risk antitrust violations by slowing generic production through patent layering.
    Paine CS
    Seton Hall Law Rev; 2003; 33(2):479-510. PubMed ID: 12715807
    [No Abstract]   [Full Text] [Related]  

  • 7. The Food and Drug Administration and patent law at a crossroads: the listing of polymorph patents as a barrier to generic drug entry.
    Srivastava D
    Food Drug Law J; 2004; 59(2):339-54. PubMed ID: 15298015
    [No Abstract]   [Full Text] [Related]  

  • 8. Amendment to UK Patent Act provides further exception to patent infringement.
    Sklan A
    Pharm Pat Anal; 2014 Jul; 3(4):349. PubMed ID: 25291308
    [No Abstract]   [Full Text] [Related]  

  • 9. Drug costs threaten patent protection.
    Cimons M
    Nat Med; 2003 Jan; 9(1):9. PubMed ID: 12514706
    [No Abstract]   [Full Text] [Related]  

  • 10. Generics battle brand names over mortality of drug patents.
    Betz R
    J Healthc Resour Manag; 1995 Jul; 13(7):35-7. PubMed ID: 10144008
    [No Abstract]   [Full Text] [Related]  

  • 11. Pharmaceutical companies and the UNITAID patent pool.
    't Hoen E
    Lancet; 2010 Jan; 375(9708):30. PubMed ID: 20109862
    [No Abstract]   [Full Text] [Related]  

  • 12. Repercussions of the Drug Price Competition and Patent Term Restoration Act of 1984.
    Hogan GF
    Am J Hosp Pharm; 1985 Apr; 42(4):849-51. PubMed ID: 4014238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Revitalizing the patent system to incentivize pharmaceutical innovation: the potential of claims with means-plus-function clauses.
    Tang WL
    Duke Law J; 2013 Feb; 62(5):1069-108. PubMed ID: 25330553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Promega changes tack in battle over patent.
    Knight J
    Nature; 2003 Nov; 426(6965):373. PubMed ID: 14647346
    [No Abstract]   [Full Text] [Related]  

  • 15. Patent infringement. Generic HIV drugmaker's patent claim is time-barred.
    AIDS Policy Law; 2003 Aug; 18(16):6. PubMed ID: 14626916
    [No Abstract]   [Full Text] [Related]  

  • 16. Drug patent protection: how long is long enough?
    Sibbald B
    CMAJ; 2001 May; 164(9):1331. PubMed ID: 11341146
    [No Abstract]   [Full Text] [Related]  

  • 17. TPA patent battle rages in United Kingdom.
    Johnston K
    Nature; 1987 Jun 11-17; 327(6122):450. PubMed ID: 3108671
    [No Abstract]   [Full Text] [Related]  

  • 18. European Commission targets drug firms over illegal patent protection.
    Watson R
    BMJ; 2010 Jan; 340():c268. PubMed ID: 20080819
    [No Abstract]   [Full Text] [Related]  

  • 19. Relationships between the academic community and the pharmaceutical industry: the legislative background and its effect on spending on medical research and development.
    Matthews JH
    Clin Invest Med; 1996 Dec; 19(6):470-8. PubMed ID: 8959357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Better protection for patentees: preliminary injunctions in the EU for pharmaceutical patent matters.
    von Falck A; Gundt M
    Pharm Pat Anal; 2013 May; 2(3):291-3. PubMed ID: 24237054
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.